Osmol Therapeutics

Osmol Therapeutics is developing OSM-0205, our lead investigational candidate, to address the urgent need of patients faced with the challenges of chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI)- challenging and debilitating conditions impacting cancer patients worldwide. Nearly 50% of patients receiving taxane-based therapy must choose between risking sub-optimal cancer treatment outcomes associated with reducing chemotherapy dosage or the painful and debilitating impact of CIPN and CICI – conditions for which there are no effective treatments. Our groundbreaking approach aims to prevent CIPN and CICI before they impact patients – paving the way for optimal chemotherapy dosing and enhanced outcomes. OSM-0205, delivered intravenously just before chemotherapy, targets the essential interaction that initiates the calcium surge to prevent the cascade of neuronal damage leading to CIPN and CICI. Osmol Therapeutics is a privately held clinical stage biopharma company advancing a first-in-class treatment to prevent CIPN, based on the groundbreaking research of Dr. Barbara Ehrlich of Yale University, founder and chief scientific officer. For more information, please visit GUIDELINES* We value open discussions and encourage sharing insightful content about biotechnology, research advancements, and industry news. We encourage a respectful and collaborative environment where diverse perspectives are appreciated, and professional conduct is upheld at all times. Osmol reserves the right to hide, delete, or block messages and users we deem inappropriate on our LinkedIn page.